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Abstract
Five hundred and seventy-eight strains of group A streptococci (GAS) isolated mostly from paediatric pharyngeal swabs were tested
to evaluate their susceptibility to erythromycin. Resistant strains were then tested for their MICs to erythromycin and clindamycin, their
phenotype of resistance to macrolides-lincosamides-streptogramin (MLSB) and for the presence of macrolide resistance genes. The rate of
resistance to erythromycin was 8.2%. Constitutive, inducible and M phenotypes of resistance were detected in 2.1, 2.1 and 95.8% of resistant
strains, respectively. All M phenotypes harboured the mefA gene, whereas constitutive and inducible phenotypes had ermB and ermTR genes,
respectively.
© 2003 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
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1. Introduction
Streptococcus pyogenes (Lancefield group A Streptococ-
cus, GAS) is one of the most common human pathogens,
being the responsible for the majority of cases of sore throat
in paediatric patients [1]. Even after 50 years of use, peni-
cillin remains the antibiotic of choice in the treatment of
GAS infection, since S. pyogenes is still exquisitely sensi-
tive to -lactams.
In patients allergic to -lactams, macrolides are an alter-
native for treatment of GAS infection. GAS resistance to
erythromycin has been first described in the UK shortly after
the introduction of the antibiotic into clinical practice [2].
After this and till the early 1970s, when higher rates were
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reported in Japan [3,4], erythromycin-resistant GAS strains
were only occasionally isolated [5].
The newer erythromycin derivatives are being preferen-
tially used for treatment of GAS pharyngitis in community
medicine and empirical chemotherapy of respiratory tract
infections because of their clinical efficacy, good tissue
penetration and phamacokinetics, allowing less frequent
dosing [6]. Meanwhile, over the past few years, increased
rates of erythromycin resistance have been reported for
GAS in several countries [7–17]. A positive association
between macrolides use and increase in resistance was re-
ported in Finland [18]. Furthermore, a significant reduction
in the frequency of resistance was reported after an ac-
tive reduction in prescription of macrolides for outpatient
therapy [19].
Up to now there are two known mechanisms of macrolide
resistance in GAS [20]. Methylation of 23S rRNA due to
ermB- or ermTR-encoded methylase results in the inabil-
ity of all macrolides, lincosamides and streptogramin B
to bind to their target site in the 50 S ribosomal subunit
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(MLS type). The methylase can be expressed constitutively
(cMLS phenotype) or inducibly (iMLS phenotype). The
second mechanism, giving the M phenotype, involves
energy-dependent efflux of 14- and 15-membered but not
16-memebered macrolides, lincosamides and streptogramin
B. The membrane-protein involved is encoded by the mefA
gene [20–22].
The first report about GAS erythromycin resistant strains
in Argentina was in 1995 [23,24]. At that time, resistant
strains were only sporadically observed (1.5%). In 1997,
a multicentre study involving centres all over the country
was published, confirming previously reported low preva-
lence (1.5%) of erythromycin resistant GAS but indicating
a different regional distribution of resistant strains [25]. In
2000, a regional study showed 11% resistance, a higher value
than previous reports but similar to that of the former re-
port from the same region [26]. In 2001, the latest report
coming from 42 centres from the central part of the coun-
try showed an increasing 7.2% of erythromycin resistant
GAS [27].
Despite resistance level surveillance in our country, there
is no published report on the phenotypes and genetic mech-
anisms involved in GAS macrolides resistance.
The purpose of this multicentric study was to determine
the susceptibilities to macrolides of GAS, and to establish
the prevalent phenotype and genetic mechanism of resistance
involved.
2. Materials and methods
2.1. Bacterial strains
A total of 568 non-related isolates of S. pyogenes recov-
ered from eight institutions (listed in acknowledgements)
were studied at the Faculty of Pharmacy and Biochemistry,
University of Buenos Aires. All but one (coming from ear
secretion) were from paediatric pharyngeal swabs.
Strains were identified according to Facklam [28] us-
ing bacitracin disks (0004 U) and pirrollidonil arylamidase
(Laboratorios Britania, Argentina). Serology was confirmed
by a commercial latex agglutination technique (Phadebact
Streptococcus Test, Boule Diagnostics AB, Huddinge, Swe-
den). The isolates were stored in skimmed milk (Difco, Bec-
ton Dickinson Microbiology Systems, Spark, MD, USA) at
−70 ◦C, and studied after being subcultured on blood agar
prior to susceptibility tests.
2.2. Susceptibility testing
MICs of erythromycin and clindamycin (Sigma, St. Louis,
MO) were performed by an agar dilution method accord-
ing to the National Committee for Clinical Laboratory Stan-
dards guidelines [29], using Mueller Hinton agar plates sup-
plemented with 5% sheep blood. The plates were incubated
overnight at 35 ◦C (with 5% CO2 if needed).
2.3. Phenotypic detection of resistance mechanisms
The resistance phenotypes of erythromycin-resistant GAS
were determined by the double disk test, with erythromycin
(15g) and clindamycin (2g) disks separated by 10 mm
as previously described [30]. Blunting of the clindamycin
inhibition zone near to the erythromycin disk indicated an
inducible type of MLSB resistance (iMLSB) and resistance
to both erythromycin and clindamycin indicated a consti-
tutive type of MLSB resistance (cMLSB). Susceptibility to
clindamycin with no blunting indicated the M resistance
phenotype.
2.4. PCR-based detection of resistance genes
The primers used to detect ermA, ermB, ermC, ermTR
and mefA in S. pyogenes were those previously described
by Sutcliffe et al. [31]. DNA amplification was performed
as follows: a single colony from a 24 h blood agar plate
was resuspended in 20l of milliQ water and heated for
10 min at 100 ◦C in a Biometra T-Gradient thermocycler
(Göttinngen, Germany). Then a mix containing 50 mM
KCl, 10 mM Tris–HCl pH 9.0, 2.5 mM MgCl2, 0.1% Triton
X-100, 0.01% gelatin, 0.2 mM deoxynucleotide triphos-
phate, 2 pmol of each primer and 0.6 U of Taq polymerase
(Biotools, Madrid, Spain) was added to yield a final vol-
ume of 25l. Amplification was performed by 30 cycles of
denaturation at 95 ◦C for 1 min, primer annealing at 54 ◦C
for 1 min and extension at 72 ◦C for 30 s, followed by an
extension step at 72 ◦C for 10 min. Amplicons were run
through 1.5% agarose gels, stained with ethidium bromide
and visualized with an UV transiluminator. PCR positive
controls, kindly provided by B.M. Willey (Mount Sinai
Hospital, Toronto, Canada) were used for the ermB, ermTR
and mefA genes. Erythromycin-sensitive GAS strains were
used as negative PCR controls. Amplification of DNA from
the positive controls with the corresponding primers yielded
PCR products of the expected size: 639, 540 and 348 bp for
ermB, ermTR and mefA, respectively [12].
3. Results and discussion
Of 568 GAS strains studied, 60 were resistant to ery-
thromycin, with inhibition zone diameters between 6 and
14 mm. When further investigated for their erythromycin
MIC by the agar dilution method, only 47 were viable, and
all were erythromycin resistant (MIC > 1 mg/l).
By the double disk test, 45 isolates (95.7%) were assigned
to the M phenotype, one isolate was constitutively resistant
showing the cMLSB phenotype (2.1%) and another single
isolate was inducibly resistant, expressing the iMLSB phe-
notype (2.1%).
All of the M phenotype isolates had a slightly higher than
published resistance level to erythromycin (see Table 1),
while clindamycin MICs values were in good agreement
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Table 1
Distribution of phenotypes, macrolide susceptibility ranges and phenotypes of resistant SGA
Resistance
phenotype
No. of isolates % Antibiotic MIC (mg/l) Resistance
genotype50% 90% Range
M 45 95.7 Erythromycin 32 64 8–64 mefA
Clindamycin 0.125 0.25 0.032–0.5
cMLSB 1 2.1 Erythromycin – – >128 ermB
Clindamycin – – >128
iMLSB 1 2.1 Erythromycin – – 64 ermTR
Clindamycin 0.125 0.5 0.125–0.5
with reported data from different countries and were the
same as those for the erythromycin-susceptible strains.
The mefA gene was present in all of the strains showing
the M-resistance phenotype.
The isolate expressing a cMLSB phenotype was highly
resistant to both erythromycin and clindamycin (MICs >
128 mg/l), and its characterization was confirmed genotypi-
cally by the presence of the ermB gene.
The inducible phenotype isolate harbouring the ermTR
gene (now considered a variant of ermA) [32,33], had MIC
values similar to those reported previously.
Genes coding for both resistance mechanisms were not
found in the same SGA strain. No amplification was detected
in any of the strains when primers specific for ermA or ermC
were used in PCR.
Of the Argentinean GAS isolates studied, 8.27% were
resistant to erythromycin using the agar dilution method.
This means that, even if this value remains relatively low
when compared with those from others countries, in the
last 5 years, erythromycin resistance rates have increased
five-fold in our country.
The predominant phenotype was M and was present in
more than 95% of analyzed erythromycin-resistant GAS.
The high incidence of the M-resistant phenotype found in
this study agrees with published results from others groups
indicating that the efflux pump MefA-resistance mediated
mechanism is also predominant in Europe.
When compared with some European countries, our re-
sistance rate remains relatively low, and hopefully, stabi-
lized, suggesting that erythromycin and clindamycin remain
as possible alternatives for the treatment of SGA infections.
Careful usage of macrolide antibiotics and continued surveil-
lance of resistance rate is advisable.
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